The pharmacokinetics and bone concentrations of oritavancin were investigated after a single intravenous dose was administered to rabbits. The pharmacokinetic profile of oritavancin in rabbits showed that it is rapidly distributed to bone tissues, with concentrations remaining stable for up to 168 h, the last measured time point. Based on these findings, further evaluation of oritavancin for the treatment of infections in bone tissues is warranted. (2) and rapid concentration-dependent bactericidal activity in vitro against a variety of Gram-positive species, including drug-resistant enterococci, staphylococci, and streptococci (3). Oritavancin is characterized by a long half-life (4), which allows for the treatment of ABSSSI with a single dose of the drug (Orbactiv package insert [1]).
point) were administered a 20-mg/kg dose of oritavancin. This dose was selected subsequently to the pharmacokinetic study in serum, as it provided an exposure close to the 1,200-mg single dose in humans. Blood samples were collected at 0.08, 3, 6, 14, 24, 48 , and 168 h after dosing via the central ear artery. Late blood sampling at 168 h was selected based on the serum concentrations observed at the last time points during the pharmacokinetic (PK) serum study, including a consideration of the long terminal half-life seen in humans (4) . Following blood sampling, rabbits were euthanized by an overdose of sodium pentobarbital (120 mg/kg, intravenous), and both tibias were harvested from each animal, dissected to be free of soft tissue, and flash frozen in liquid nitrogen.
Pharmacokinetic sample treatment. After collection, the blood samples were allowed to clot for 30 min and then centrifuged at 1,300 ϫ g for 15 min at 4°C. The serum was transferred to a new tube and kept frozen at Ϫ25°C until bioanalysis. Once the left tibia bone was collected and totally cleaned of soft tissue, it was incubated for 5 min in liquid nitrogen and cracked with clamps. The bone matrix and bone marrow were easily physically separated and placed in separate tubes. The bone marrow samples were weighed and stored frozen at Ϫ25°C until bioanalysis. The bone matrix obtained from the left tibia and the whole tibia of the right leg were pulverized separately using a metal ball mill. The samples were stored frozen at Ϫ25°C until bioanalysis. The levels of oritavancin in serum and bone tissues were determined using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Bioanalytical method for serum. Serum samples were spiked with 0.1% Tween 80 in water and then diluted with acetonitrile acidified with 0.1% formic acid (FA). After centrifugation, the supernatants were collected and concentrated to dryness. The residue was reconstituted in the initial mobile phase and loaded onto a Zorbax SB-Aq (3.5 m, 2.1 by 30 mm) column and eluted with 10 to 80% of 0.1% FA in methanol in 0.1% FA in H 2 O over 5 min. Vancomycin was used as the internal standard. MS detection was performed in multiple reaction monitoring (MRM) mode on an Agilent LC/MS Ion Trap using the 598 (m/z 3ϩ) to 827 (m/z 2ϩ) to 201 (m/z 1ϩ) transitions for oritavancin and the 725 (m/z 2ϩ) to 1,305 (m/z 1ϩ) transition for vancomycin. The method relied on calibration curves using seven standard concentrations injected in duplicate over the range of 12.5 to 1,000 ng/ml.
Bioanalytical method for bone. Direct isolation of oritavancin from bone suffered from very low and highly variable recovery. Given the chemically fragile nature of the molecule, which precludes the use of extremes of temperature or pH in particular and its poor solubility in any nonaqueous medium, the options for the direct extraction of oritavancin from bone were limited. As a result, an indirect method was developed, relying on the acidic degradation of oritavancin. The assessment of oritavancin concentrations in bone matrix, bone marrow, and the whole tibia were performed using an indirect method. In these matrices, oritavancin concentrations were determined by detection of the acidic degradation product of oritavancin, 4-(4-chlorophyl)benzyl-4-epi-vancosamine (CBV). The methods relied on calibration curves using oritavancin standards treated through the same process as the samples injected in triplicate for detection of CBV. The initial set of standards had seven concentrations for bone matrix (0.2 to 20 ng/mg of bone matrix), six concentrations for bone marrow (2.5 to 100 ng/mg of bone marrow), and six concentrations for tibia (1 to 40 ng/mg of bone). The dynamic range was defined by the performance of the standards, with standards at Ͼ15% of the nominal values (Ͼ20% at lower limit of quantitation) excluded. This resulted in dynamic ranges of 2 to 20 ng/mg for bone matrix, 2.5 to 100 ng/mg for bone marrow, and 2 to 20 ng/mg for tibia. A sample (100 l for bone marrow homogenate samples and 50 mg for bone matrix and tibia powder samples) was suspended in 1 N hydrochloric acid (1 ml for bone marrow homogenate samples and 0.5 ml for bone matrix and tibia samples) and incubated for 5 min at 70°C. For tibia and bone matrix samples, the pellet was treated three times under these conditions. After centrifugation, the supernatant was transferred to a new tube. The determination of CBV in the pooled supernatants was performed as follows: the pooled supernatants were spiked with a solution of the internal standard (eperezolid) and concentrated by solid-phase extraction on Strata-X cartridges using 5% FA in methanol as the eluent. After evaporation, the residue was reconstituted in a mixture of 0.1% FA in H 2 O and 0.1% FA in a 1:1 methanol to acetonitrile ratio, injected onto a Gemini C6 phenyl column Pharmacokinetic analysis. In the serum-only pharmacokinetic study, parameters were calculated for each rabbit and then averaged per dose. In the bone pharmacokinetic study, the mean oritavancin concentrations in serum and bone tissues were calculated at each time point before analysis. Serum, bone matrix, bone marrow, and whole tibia concentrations were analyzed by noncompartmental analysis (NCA) using Phoenix WinNonlin version 6.3 (Certara, Mountain View, CA, USA) to determine the maximum concentration (C max ), the time to C max (T max ), the area under the concentration-time curve (AUC), and clearance. The terminal halflife was calculated using the last 3 time points.
RESULTS

Serum pharmacokinetics.
Four groups of three rabbits were administered ascending intravenous 5-min infusions of oritavancin ranging from 10 to 40 mg/kg. All doses were well tolerated by the animals. The serum concentration-versus-time profiles for the four doses are presented in Fig. 1 , and the pharmacokinetic parameters are presented in Table 1 . The mean oritavancin C max values in serum were 71.79, 113.14, 147.73, and 252.39 g/ml at doses of 10, 15, 20, and 40 mg/kg, respectively. Twenty-four hours after the start of infusion, the oritavancin concentrations were 3.14 to 17.74 g/ml for doses of 10, 15, 20, and 40 mg/kg. The mean AUC from 0 to 24 h (AUC 0 -24 ) values were 449.89, 785.81, 966.37, and 1,834.85 g · h/ml at doses of 10, 15, 20, and 40 mg/kg, respectively. Based on these data, the 20-mg/kg dose was selected for further study in rabbits, given that the AUC 0 -24 is close to the one observed in humans after having received a single 1,200-mg dose (approximately 1,110 g · h/ml [4] ).
Analysis of the oritavancin serum concentrations obtained during the bone pharmacokinetic study showed that oritavancin was still detected at 168 h postadministration of 20 mg/kg of drug. The mean (n ϭ 3/time point) concentration-versus-time curves for oritavancin in serum are illustrated in Fig. 2 , and pharmacokinetic parameters are listed in Table 2 . The C max (219.3 g/ml) was reached rapidly, and the level of oritavancin declined more quickly between 0.08 h and 48 h compared to that between 48 h and 168 h postdose. During that last phase, the terminal half-life in serum was 62.4 h. The calculated area under the concentrationtime curve from 0 to 168 h (AUC 0 -168 ) in serum was 1,672.2 g · h/ml. Bone pharmacokinetics. Oritavancin was present in all time points over the entire 168-h study period. The mean (n ϭ 3/time point) concentration-versus-time curves for oritavancin in whole tibia, bone matrix, and bone marrow over the 168-h time period following a single 5-min intravenous infusion of 20 mg/kg are shown in Fig. 2 , and the pharmacokinetic parameters are listed in Table 2 . In bone, the C max ranged from 14.2 to 34.5 g/g. The calculated AUC 0 -168 values in bone tissues were 1,792.1, 2,779.5, and 5,136.3 g · h/g in whole tibia, bone matrix, and bone marrow, respectively. The AUC 0 -168 values in whole tibia, bone matrix, and bone marrow were 1.1, 1.7, and 3.1 times higher than that in serum, respectively. Clearance values, calculated using AUC 0 -168 in whole tibia, bone matrix, and bone marrow (11.2, 7.2, and 3.9 g/h/kg, respectively) were also lower than that in serum (12.0 ml/h/kg).
DISCUSSION
In the present studies, the concentrations of oritavancin in serum and bone tissues were successfully determined using an LC-MS/MS method. At a dose of 20 mg/kg in the rabbit (equivalent to a 1,200-mg dose in humans), oritavancin concentrations are Ն10 g/ml in serum for Ն24 h following a single dose. These concentrations are severalfold above the MIC 90 for S. aureus (0.06 g/ml [9] [10] [11] ) and Streptococcus pneumoniae (Յ0.008 g/ml [12, 13] ). These exposures correlate well with the efficacy data observed in the rabbit models of endocarditis caused by methicillin-resistant S. aureus (14) and of meningitis caused by S. pneumoniae (15, 16) .
In this study, the differential distribution of oritavancin from serum to bone tissue was determined. Concentrations of oritavancin in specific compartments were determined from whole bone by comparing the concentration in bone matrix versus that in bone marrow compartments. Following a single dose of 20 mg/kg in the rabbit (equivalent to a 1,200-mg dose in humans), oritavancin concentrations in the bone tissues were above the S. aureus MIC 90 immediately after the infusion and remained above the MIC 90 until the end of the study (168 h). However, it should be highlighted that these are the total concentrations, and the active fraction of oritavancin in bone remains unknown. The concentrations obtained in this study represent concentrations of oritavancin in the whole homogenized tissue; the study did not address the level of oritavancin in specific compartments of the tissue. Tissues are composed of distinct compartments (extra-and intracellular or subcellular organelles). The active concentration is determined based on the concentration of the drug at the site (in the compartment) of the infection. For extracellular infections, homogenization of the tissue dilutes drugs that are mainly located in the extracellular compartment, which may lead to an underestimation of the active concentration of drug (17) . Oritavancin is known to accumulate intracellularly within macrophages (18, 19) . In this case, total oritavancin concentrations in tissue may be overestimated if the infection is extracellular and underestimated if it is intracellular. The determination of the active free oritavancin concentration is complicated by the drug binding to filters and dialysis membrane (20) (21) (22) . Consequently, the use of alternative techniques, such as a microdialysis catheter, would not provide reliable results because of the unspecific surface binding properties of oritavancin. In the neutropenic mouse thigh infection model, Boylan and colleagues (23) found that infection was not affecting the pharmacokinetics of oritavancin; however, the pharmacokinetic and bone distribution of oritavancin in infected rabbits remain to be evaluated. The pharmacokinetic profile of oritavancin in the rabbit showed that it rapidly distributes to the bone, where concentrations remain stable for up to 168 h, the last measured time point in this study. While the oritavancin C max was higher in serum, the exposure (AUC) was higher in bone tissues. The long terminal half-life seen in rabbit serum was not surprising based on the one seen in humans (245 h) (4). The two rabbit studies provided similar serum concentrations at 20 mg/kg, with a combined average AUC 0 -24 of 1,189 g · h/ml. This exposure correlates well with that found for a 1,200-mg dose in humans, with an AUC 0 -24 of 1,100 g · h/ml (4). The bone concentrations of oritavancin following a 20-mg/kg dose were similar to those in a previous study (24) . Two other published studies measured the concentrations of oritavancin in rabbit serum, with oritavancin administered intramuscularly in one (25) and intravenously in the other (26) . In the present studies, the concentrations of oritavancin in serum were slightly higher than those published previously by Lefort and colleagues (26) . A different bioanalytical method was used in the manuscript published by Lefort et al. They used a method that was developed to profile vancomycin (27) . That method used gradient high-performance liquid chromatography for the determination of vancomycin-related substances. Considering the difference in the bioanalytical methods used and the normal variability between pharmacokinetic studies, the data were considered similar overall (26) .
Oritavancin bone penetration, defined as the tissue-to-serum AUC 0 -168 ratio, was 1.7 and 3.1 in bone matrix and bone marrow, respectively. Swoboda and colleagues (28) reported that linezolid and vancomycin penetrate bone at 11 and 28%, respectively, while the mean ratios of tissue concentration to blood concentration of teicoplanin were close to 1 and 1.5 in bone and bone marrow, respectively (29) . Dalbavancin had a higher bone penetration than these drugs, with tissue-toplasma AUC 0 -336 ratios of 0.63 and 2.48 in bone and bone marrow, respectively (30), but it is lower than that observed for oritavancin. Oritavancin bone penetration is thus higher than that of linezolid, vancomycin, teicoplanin, and dalbavancin.
Considering that the concentrations of oritavancin obtained in this study and those of the cited comparators represent total drug concentrations, and that the active fraction of each drug in bone remains to be elucidated, the pharmacokinetic/pharmacodynamic (PK/PD) relationship of oritavancin in bone and other tissues should be evaluated cautiously. Overall, following 5-min intravenous infusions of oritavancin to male New Zealand White rabbits, serum concentrations remained above the MIC 90 of common Gram-positive pathogens implicated in bacteremia and bone infections for Ն24 h postdose at all doses tested, and the bone concentrations remained above the MIC 90 of S. aureus for Ն168 h following a single dose of 20 mg/kg. Considering the data, further evaluation of oritavancin for the treatment of infections found in bone tissues is warranted.
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